DavidAJacobsohnMDScM

Pediatric Hematology & Oncology • Washington, DC

Professor, Pediatrics, George Washington University School of Medicine and Health Sciences

Join to view full profile

Dr. Jacobsohn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jacobsohn's full profile

Already have an account?

Office
111 Michigan Ave
Washington, DC 20010
Phone+1 888-884-2327

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
Johns Hopkins UniversityResidency, Pediatrics, 1996 - 1999
Tufts University School of MedicineClass of 1996

Certifications & Licensure

MD State Medical License 2000 - 2026
VA State Medical License 2020 - 2026
DC State Medical License 2010 - 2024
IL State Medical License 2002 - 2011
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors:Washington DC Area Castle Connolly, 2012

Clinical Trials

Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children Start of enrollment: 2004 Jan 01
Completed
Phase 2
Markers of Inflammation in Hematopoietic Stem Cell Transplant Start of enrollment: 2007 Apr 01
Completed
Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease Start of enrollment: 2008 Jan 01
Completed
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Start of enrollment: 2008 May 01
Unknown status
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Abatacept as GVHD Prophylaxis Phase 2 Start of enrollment: 2013 Feb 01
Active, not recruiting
Phase 2
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Start of enrollment: 2014 Mar 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2249 citations
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
Madan Jagasia, Hildegard T. Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff
Biology of Blood and Marrow Transplantation. 2015-03-01
882 citations
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Wor...
Madan H Jagasia, Hildegard T Greinix, Mukta Arora, Kirsten M Williams, Daniel Wolff
Biology of Blood and Marrow Transplantation. 2015-03-01
297 citations
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Sally Arai, Mukta Arora, Tao Wang, Stephen R. Spellman, Wensheng He
Biology of Blood and Marrow Transplantation. 2015-02-01

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Veno-Occlusive Disease After High-Dose Busulfan–Melphalan in Neuroblastoma
Gregory Yanik, Morris Kletzel, Stephan Grupp, David Jacobsohn, Christopher C Dvorak, Alix E Seif, Mark Ranalli, Haydar Frangoul, Nature

Abstracts/Posters

Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)
David Jacobsohn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)Cl...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

First Patient Begins Newly Approved Sickle Cell Gene TherapyOctober 21st, 2024
Liaison's Fully AGNIS-Compatible BMT Registry to Debut at BMT Tandem MeetingsJanuary 26th, 2016
Multi-Institutional Prospective Research of Expanded Multi-Antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)July 30th, 2014
Join now to see all